New drug shows promise for rare liver condition
NCT ID NCT03946449
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tested a new drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The goal was to see if the drug is safe and can reduce harmful protein buildup in the liver. Participants received multiple doses of the drug by injection, and researchers measured changes in liver protein levels and other health markers over 24 to 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Center 1
Vienna, 1090, Austria
-
Research Center 1
Aachen, 52074, Germany
-
Research Center 2
Edinburgh, EH19 3BJ, United Kingdom
-
Research Center 3
Cambridge, CB2 0QQ, United Kingdom
Conditions
Explore the condition pages connected to this study.